+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Orphan Drugs Market by Therapeutic Area, Product Type, Administration Route, Distribution Channel, Patient Type, Payer Type - Global Forecast to 2030- Product Image
Orphan Drugs Market by Therapeutic Area, Product Type, Administration Route, Distribution Channel, Patient Type, Payer Type - Global Forecast to 2030- Product Image
Sale

Orphan Drugs Market by Therapeutic Area, Product Type, Administration Route, Distribution Channel, Patient Type, Payer Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674387
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The orphan drugs market is evolving rapidly, driven by innovation, shifting regulatory expectations, and growing collaboration across industry and academic environments. Senior decision-makers increasingly seek actionable insights to navigate complexities, optimize investments, and support sustainable therapies for rare conditions.

Market Snapshot: Orphan Drugs Market Trends and Growth Outlook

The orphan drugs market grew from USD 216.80 billion in 2024 to USD 246.85 billion in 2025. It is expected to continue expanding at a CAGR of 13.48%, reaching USD 463.09 billion by 2030. Regulatory initiatives, scientific breakthroughs, and ongoing partnerships between global biopharmaceutical firms and research organizations propel this upward trend. Key concerns include limited patient populations, nuanced regulatory pathways, and a growing expectation for real-world evidence to support payer negotiations and long-term access.

Scope & Segmentation: Comprehensive View of Market Opportunities

  • Therapeutic Areas: Immunology, Infectious Diseases, Metabolic Disorders, Neurology, Oncology
  • Product Types: Biologics (Enzymes, Monoclonal Antibodies, Recombinant Proteins), Gene Therapy (Non-Viral Vector, Viral Vector), Small-Molecule, Tissue Therapy
  • Administration Routes: Inhalation, Injectable (Intramuscular, Intravenous, Subcutaneous), Oral, Topical
  • Distribution Channels: Direct-To-Patient, Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
  • Patient Types: Adult, Pediatric
  • Payer Types: Government Programs, Out-Of-Pocket, Private Insurance
  • Regions Covered: Americas (United States—including California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio—Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Leading Companies: F. Hoffmann-La Roche Ltd, Johnson & Johnson, Novartis AG, Pfizer Inc., Sanofi S.A., Bristol-Myers Squibb Company, Amgen Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., BioMarin Pharmaceutical Inc.

Key Takeaways for Senior Decision-Makers

  • Innovation in gene therapies and precision biologics is accelerating the commercial availability of treatments for rare and underserved conditions.
  • Complex clinical trial designs, elevated development costs, and fragmented patient populations require adaptive development strategies and early integration of regulatory insight.
  • Collaboration among biotech startups, academic institutions, and global pharmaceutical companies fosters an ecosystem focused on patient-centric outcomes and rapid innovation cycles.
  • Value-based pricing models and risk-sharing agreements are gaining traction as stakeholders increasingly prioritize demonstrable long-term patient benefit over traditional reimbursement metrics.
  • Regional market dynamics drive differentiation in access frameworks, with developed economies prioritizing expedited approvals and emerging markets leveraging technology transfer for affordability.
  • Early stakeholder engagement—including with patient advocacy groups—improves the alignment of development programs with genuine unmet needs and enhances trial participation rates.

Tariff Impact: Navigating New U.S. Trade Policy Dynamics

Recent U.S. tariff policies affecting active pharmaceutical ingredients and specialized equipment have prompted manufacturers to diversify supplier networks and boost domestic capacity. Strategic alliances with logistics partners and investments in onshore production are key tactics for ensuring stability. Proactive pricing strategies now incorporate tariff index-linked clauses to mitigate risk and protect margins, aiding negotiation with payers and maintaining continuity in patient access. The impact extends to scenario planning, inventory management, and the necessity for robust collaboration across the value chain.

Methodology & Data Sources

This report uses a research model that integrates primary interviews with industry leaders, regulatory authorities, clinical experts, and payer representatives. Secondary analysis covers scientific literature, regulatory filings, financial data, and market reports. Data triangulation ensures accuracy, while subject matter peer review validates findings and recommendations.

Why This Report Matters

  • Delivers a multi-dimensional analysis helping executives refine development and commercialization strategies in a fast-changing orphan drug landscape.
  • Equips decision-makers with segmentation insights, regional trends, and strategic recommendations to optimize resource allocation and maximize stakeholder alignment.
  • Supports assessment of emerging risks and opportunities linked to regulatory policy changes, technology adoption, and supply chain management.

Conclusion

The orphan drugs market presents expanding opportunities, yet demands strategic agility and stakeholder coordination. This report equips senior leaders to navigate evolving regulations, access barriers, and shifting value expectations with confidence and data-driven clarity.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Orphan Drugs Market, by Therapeutic Area
8.1. Introduction
8.2. Immunology
8.3. Infectious Diseases
8.4. Metabolic Disorders
8.5. Neurology
8.6. Oncology
9. Orphan Drugs Market, by Product Type
9.1. Introduction
9.2. Biologics
9.2.1. Enzymes
9.2.2. Monoclonal Antibodies
9.2.3. Recombinant Proteins
9.3. Gene Therapy
9.3.1. Non-Viral Vector
9.3.2. Viral Vector
9.4. Small-Molecule
9.5. Tissue Therapy
10. Orphan Drugs Market, by Administration Route
10.1. Introduction
10.2. Inhalation
10.3. Injectable
10.3.1. Intramuscular
10.3.2. Intravenous
10.3.3. Subcutaneous
10.4. Oral
10.5. Topical
11. Orphan Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Direct-To-Patient
11.3. Hospital Pharmacy
11.4. Online Pharmacy
11.5. Retail Pharmacy
12. Orphan Drugs Market, by Patient Type
12.1. Introduction
12.2. Adult
12.3. Pediatric
13. Orphan Drugs Market, by Payer Type
13.1. Introduction
13.2. Government Programs
13.3. Out-Of-Pocket
13.4. Private Insurance
14. Americas Orphan Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Orphan Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Orphan Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. F. Hoffmann-La Roche Ltd
17.3.2. Johnson & Johnson
17.3.3. Novartis AG
17.3.4. Pfizer Inc.
17.3.5. Sanofi S.A.
17.3.6. Bristol-Myers Squibb Company
17.3.7. Amgen Inc.
17.3.8. Takeda Pharmaceutical Company Limited
17.3.9. AbbVie Inc.
17.3.10. BioMarin Pharmaceutical Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ORPHAN DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ORPHAN DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ORPHAN DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ORPHAN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ORPHAN DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ORPHAN DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ORPHAN DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ORPHAN DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ORPHAN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ORPHAN DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ORPHAN DRUGS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ORPHAN DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ORPHAN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ORPHAN DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ORPHAN DRUGS MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ORPHAN DRUGS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ORPHAN DRUGS MARKET SIZE, BY SMALL-MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ORPHAN DRUGS MARKET SIZE, BY TISSUE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ORPHAN DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ORPHAN DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ORPHAN DRUGS MARKET SIZE, BY DIRECT-TO-PATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ORPHAN DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ORPHAN DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ORPHAN DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ORPHAN DRUGS MARKET SIZE, BY GOVERNMENT PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ORPHAN DRUGS MARKET SIZE, BY OUT-OF-POCKET, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ORPHAN DRUGS MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ORPHAN DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 65. CANADA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 66. CANADA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 67. CANADA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 68. CANADA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 69. CANADA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 70. CANADA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 71. CANADA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. CANADA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 73. CANADA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 75. MEXICO ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 76. MEXICO ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 77. MEXICO ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 78. MEXICO ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 79. MEXICO ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 80. MEXICO ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. MEXICO ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 82. MEXICO ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 120. GERMANY ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 121. GERMANY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 122. GERMANY ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 123. GERMANY ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 124. GERMANY ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 125. GERMANY ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 126. GERMANY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. GERMANY ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 128. GERMANY ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 129. FRANCE ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 130. FRANCE ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 131. FRANCE ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 132. FRANCE ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 133. FRANCE ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 134. FRANCE ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 135. FRANCE ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. FRANCE ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 137. FRANCE ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 147. ITALY ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 148. ITALY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 149. ITALY ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 150. ITALY ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 151. ITALY ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 152. ITALY ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 153. ITALY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. ITALY ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 155. ITALY ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 156. SPAIN ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 157. SPAIN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 158. SPAIN ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 159. SPAIN ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 160. SPAIN ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 161. SPAIN ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 162. SPAIN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. SPAIN ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 164. SPAIN ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 173. UNITED ARAB EMIRATES ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. SAUDI ARABIA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. SOUTH AFRICA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 191. SOUTH AFRICA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 192. DENMARK ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 193. DENMARK ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 194. DENMARK ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 195. DENMARK ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 196. DENMARK ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 197. DENMARK ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 198. DENMARK ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. DENMARK ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 200. DENMARK ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. NETHERLANDS ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 209. NETHERLANDS ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 210. QATAR ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 211. QATAR ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 212. QATAR ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 213. QATAR ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 214. QATAR ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 215. QATAR ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 216. QATAR ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. QATAR ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. QATAR ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 219. FINLAND ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 220. FINLAND ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 221. FINLAND ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 222. FINLAND ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 223. FINLAND ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 224. FINLAND ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 225. FINLAND ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. FINLAND ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 227. FINLAND ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. SWEDEN ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 236. SWEDEN ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 245. NIGERIA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 246. EGYPT ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 247. EGYPT ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 248. EGYPT ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 249. EGYPT ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 250. EGYPT ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 251. EGYPT ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 252. EGYPT ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. EGYPT ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 254. EGYPT ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 255. TURKEY ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 256. TURKEY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 257. TURKEY ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 258. TURKEY ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 259. TURKEY ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 260. TURKEY ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 261. TURKEY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. TURKEY ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 263. TURKEY ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 273. NORWAY ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 274. NORWAY ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 275. NORWAY ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 276. NORWAY ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 277. NORWAY ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 278. NORWAY ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 279. NORWAY ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. NORWAY ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 281. NORWAY ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 282. POLAND ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 283. POLAND ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 284. POLAND ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 285. POLAND ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 286. POLAND ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 287. POLAND ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 288. POLAND ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. POLAND ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 290. POLAND ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 298. SWITZERLAND ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 299. SWITZERLAND ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 306. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 308. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 309. ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 310. CHINA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 311. CHINA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 312. CHINA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 313. CHINA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 314. CHINA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 315. CHINA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 316. CHINA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. CHINA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 318. CHINA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 319. INDIA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 320. INDIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 321. INDIA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 322. INDIA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 323. INDIA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 324. INDIA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 325. INDIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 326. INDIA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 327. INDIA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 328. JAPAN ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 329. JAPAN ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 330. JAPAN ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 331. JAPAN ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 332. JAPAN ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 333. JAPAN ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 334. JAPAN ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 335. JAPAN ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 336. JAPAN ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 337. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 338. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 339. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 340. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 341. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 342. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 343. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 344. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 345. AUSTRALIA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 346. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 347. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 348. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 349. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 350. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 351. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 352. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 353. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 354. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 355. INDONESIA ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 356. INDONESIA ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 357. INDONESIA ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 358. INDONESIA ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 359. INDONESIA ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 360. INDONESIA ORPHAN DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 361. INDONESIA ORPHAN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 362. INDONESIA ORPHAN DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 363. INDONESIA ORPHAN DRUGS MARKET SIZE, BY PAYER TYPE, 2018-2030 (USD MILLION)
TABLE 364. THAILAND ORPHAN DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 365. THAILAND ORPHAN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 366. THAILAND ORPHAN DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 367. THAILAND ORPHAN DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 368. THAILAND ORPHAN DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Orphan Drugs market report include:
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • BioMarin Pharmaceutical Inc.

Table Information

Report AttributeDetails
No. of Pages186
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 246.85 Billion
Forecasted Market Value ( USD ) by 2030 $ 463.09 Billion
Compound Annual Growth Rate13.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Orphan Drugs - Global Strategic Business Report - Product Image

Orphan Drugs - Global Strategic Business Report

  • Report
  • 409 Pages
  • Global
From
Orphan Drugs Market Report by Drug Type, Disease Type, Phase, Top Selling Drugs, Distribution Channel, and Region 2025-2033 - Product Image

Orphan Drugs Market Report by Drug Type, Disease Type, Phase, Top Selling Drugs, Distribution Channel, and Region 2025-2033

  • Report
  • 148 Pages
  • Global
From
Orphan Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Orphan Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 184 Pages
  • Global
From
Orphan Drugs Market Report 2025 - Product Image

Orphan Drugs Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Orphan Drugs Market 2024-2028 - Product Image

Orphan Drugs Market 2024-2028

  • Report
  • 180 Pages
  • Global
From

About the Orphan Drug Market

The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them. The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives. Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.